+ Site Statistics
References:
52,654,530
Abstracts:
29,560,856
PMIDs:
28,072,755
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Propofol. A review of its pharmacodynamic and pharmacokinetic properties and use as an intravenous anaesthetic



Propofol. A review of its pharmacodynamic and pharmacokinetic properties and use as an intravenous anaesthetic



Drugs 35(4): 334-372



Propofol is an intravenous anaesthetic which is chemically unrelated to other anaesthetics. Induction of anaesthesia with propofol is rapid, and maintenance can be achieved by either continuous infusion or intermittent bolus injections, with either nitrous oxide or opioids used to provide analgesia. Comparative studies have shown propofol to be at least as effective as thiopentone, methohexitone or etomidate for anaesthesia during general surgery. The incidence of excitatory effects is lower with propofol than with methohexitone, but apnoea on induction occurs more frequently with propofol than with other anaesthetics. Additionally, a small number of studies of induction and maintenance of anaesthesia have found propofol to be a suitable alternative to induction with thiopentone and maintenance with halothane, isoflurane or enflurane. Propofol is particularly suitable for outpatient surgery since it provides superior operating conditions to methohexitone (particularly less movement), and rapid recovery in the postoperative period associated with a low incidence of nausea and vomiting. When used in combination with fentanyl or alfentanil, propofol is suitable for the provision of total intravenous anaesthesia, and comparative studies found it to be superior to methohexitone or etomidate in this setting. Infusions of subanaesthetic doses of propofol have been used to sedate patients for surgery under regional anaesthesia, and also to provide sedation of patients in intensive care. In the latter situation it is particularly encouraging that propofol did not suppress adrenal responsiveness during short term studies. If this is confirmed during longer term administration this would offer an important advantage over etomidate. Thus, propofol is clearly an effective addition to the limited range of intravenous anaesthetics. While certain areas of its use need further study, as would be expected at this stage of its development, propofol should find a useful role in anaesthetic practice.

(PDF emailed within 1 workday: $29.90)

Accession: 041100580

Download citation: RISBibTeXText

PMID: 3292208


Related references

Some studies on the properties of the intravenous anaesthetic, propofol ('Diprivan')--a review. Postgraduate Medical Journal 61 Suppl 3: 90-95, 1985

Intravenous anaesthetic agents. Pharmacokinetic-pharmacodynamic relationships. Clinical Pharmacokinetics 12(2): 79-110, 1987

Pregnanolone emulsion. A preliminary pharmacokinetic and pharmacodynamic study of a new intravenous anaesthetic agent. Anaesthesia 45(3): 189-197, 1990

Fenoldopam: a review of its pharmacodynamic and pharmacokinetic properties and intravenous clinical potential in the management of hypertensive urgencies and emergencies. Drugs 54(4): 634-650, 1997

Accuracy of combined pharmacokinetic/pharmacodynamic model in predicting recovery from propofol/alfentanil total intravenous anesthesia. Anesthesiology (Hagerstown) 87(3 SUPPL ): A378, 1997

Population pharmacokinetic and pharmacodynamic modeling of propofol for long-term sedation in critically ill patients: a comparison between propofol 6% and propofol 1%. Clinical Pharmacology and Therapeutics 72(6): 670-684, 2002

Effectiveness, safety, and pharmacokinetic and pharmacodynamic characteristics of microemulsion propofol in patients undergoing elective surgery under total intravenous anaesthesia. British Journal of Anaesthesia 104(5): 563-576, 2010

Evaluation of pharmacokinetic properties and anaesthetic effects of propofol in a new perfluorohexyloctane (F6H8) emulsion in rats--A comparative study. International Journal of Pharmaceutics 486(1-2): 69-76, 2016

Comparative pharmacokinetic and pharmacodynamic properties of oral and intravenous (+)-sotalol in healthy volunteers. Journal of Pharmacy and Pharmacology 46(7): 600-605, 1994

Pharmacokinetic and pharmacodynamic properties of intravenous fenoldopam, a dopamine1-receptor agonist, in hypertensive patients. British Journal of Clinical Pharmacology 25(1): 17-21, 1988

Pharmacokinetic and pharmacodynamic properties of physostigmine following steady-state intravenous infusion in subjects with Alzheimers disease. Journal of the American Geriatrics Society 42(11): SA79, 1994

Telmisartan: a review of its pharmacodynamic and pharmacokinetic properties. Expert Opinion on Drug Metabolism & Toxicology 6(7): 863-871, 2011

Methadone: a review of its pharmacokinetic/pharmacodynamic properties. Journal of Pharmacological and Toxicological Methods 42(2): 61-66, 2000